Numerous studies document that melatonin possesses a broad-spectrum antioxidant activity. It traps a number of reactive oxygen species (ROS) such as hydroxyl and peroxyl radicals, singlet oxygen and hypochlorous acid. It also inhibits peroxynitrite-induced reactions. It is known that atherosclerosis progression involves ROS-induced oxidation of low-density lipoproteins in sub-endothelial space and the depletion of nitric oxide (NO) in blood vessels, as well as a decreased sensitivity of the vessels to the actions of NO. Considering this, a series of new NO-donor antioxidants were designed and synthesized by joining melatonin with NO-donor nitrooxy and furoxan moieties as polyvalent agents potentially useful for the treatment of cardiovascular diseases involving atherosclerotic vascular changes. The in vitro antioxidant properties of the resulting products were assessed in the thiobarbituric acid reactive substances assay (TBARS), the ABTS+• as well as in the alkaline phosphatase (ALP) assay. The antioxidant capacities of NO-donor melatonins to inhibit lipoperoxidation (TBARS-IC50) was predominantly dependent on their lipophilicity, and therefore on their partitioning process into membranes. On the other hand, their comparable capacity to inhibit protein oxidation (ALP-IC50) was independent of their lipophilicity and was consistent with their similar ability to participate in electron transfer reactions. All the NO-donor melatonins were also evaluated for their ability to relax rat aorta strips precontracted with 1 μm phenylephrine. Finally, binding affinities and intrinsic activity studies, carried out at MT1 and MT2 receptor subtypes, showed a rather complex picture in need of further investigation.

NO-Donor Melatonin Derivatives: Synthesis And In Vitro Pharmacological Characterization

CHEGAEV, Konstantin;LAZZARATO, Loretta;ROLANDO, Barbara;MARINI, Elisabetta;TOSCO, Paolo;CENA, Clara;FRUTTERO, Roberta;GASCO, Alberto
2007

Abstract

Numerous studies document that melatonin possesses a broad-spectrum antioxidant activity. It traps a number of reactive oxygen species (ROS) such as hydroxyl and peroxyl radicals, singlet oxygen and hypochlorous acid. It also inhibits peroxynitrite-induced reactions. It is known that atherosclerosis progression involves ROS-induced oxidation of low-density lipoproteins in sub-endothelial space and the depletion of nitric oxide (NO) in blood vessels, as well as a decreased sensitivity of the vessels to the actions of NO. Considering this, a series of new NO-donor antioxidants were designed and synthesized by joining melatonin with NO-donor nitrooxy and furoxan moieties as polyvalent agents potentially useful for the treatment of cardiovascular diseases involving atherosclerotic vascular changes. The in vitro antioxidant properties of the resulting products were assessed in the thiobarbituric acid reactive substances assay (TBARS), the ABTS+• as well as in the alkaline phosphatase (ALP) assay. The antioxidant capacities of NO-donor melatonins to inhibit lipoperoxidation (TBARS-IC50) was predominantly dependent on their lipophilicity, and therefore on their partitioning process into membranes. On the other hand, their comparable capacity to inhibit protein oxidation (ALP-IC50) was independent of their lipophilicity and was consistent with their similar ability to participate in electron transfer reactions. All the NO-donor melatonins were also evaluated for their ability to relax rat aorta strips precontracted with 1 μm phenylephrine. Finally, binding affinities and intrinsic activity studies, carried out at MT1 and MT2 receptor subtypes, showed a rather complex picture in need of further investigation.
JOURNAL OF PINEAL RESEARCH
42
4
371
385
http://www.blackwellpublishing.com/journal.asp?ref=0742-3098
ABTS; alkaline phosphatase; antioxidants; melatonin; multitarget drugs; nitric oxide-donors; thiobarbituric acid reactive substances assay
K. CHEGAEV; L. LAZZARATO; B. ROLANDO; E. MARINI; P. TOSCO; C. CENA; R. FRUTTERO; F. BERTOLINI; M. REIST; P.A. CARRUPT; V. LUCINI; F. FRASCHINI; A. GASCO
File in questo prodotto:
File Dimensione Formato  
2007_melatonine_pineal.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 737.03 kB
Formato Adobe PDF
737.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Manuscript_melatonine.pdf

accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/41596
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact